Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease.

Samiul A MostafaR L ColemanO F AgbajeA M GrayR R HolmanM A Bethel

Published in: Diabetic medicine : a journal of the British Diabetic Association (2017)

These simulated complication rates might help inform the degree to which complications might be reduced by targeting particular HbA1c reductions in Type 2 diabetes.

Keyphrases

cardiovascular disease
type diabetes
risk factors
glycemic control
cancer therapy
metabolic syndrome
cardiovascular risk factors
skeletal muscle
drug delivery